Literature DB >> 1980167

Immunohistochemical investigation and northern blot analysis of c-erB-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri.

C Brumm1, A Rivière, C Wilckens, T Löning.   

Abstract

Seventy specimens of normal endometrium (n = 13) and cervix (n = 12), endometrial hyperplasia (n = 4), cervical dysplasia (n = 20), endometrial (n = 11) and cervical carcinoma (n = 8) and uterine metastases of mammary carcinomas (n = 2) have been analysed for c-erB-2 expression with immunohistochemistry employing a monoclonal anti ERBB-2 antibody and Northern-blot hybridization using single stranded RNA probes. In comparison with the c-erbB-2 mRNA expression level found in normal samples, two advanced and poorly differentiated endometrial adenocarcinomas (FIGO IV) and two ductal mammary carcinomas which had metastasized to the uterus, together with three carcinomas in situ of the cervix, showed c-erbB-2 enhanced transcription level. All other endometrial samples including adenomatous hyperplasia and nine endometrial carcinomas (FIGO I), and all other lesions of squamous epithelial origin displayed transcriptional activities at or below the baseline level. Immunohistochemical study of ERBB-2 protein expression showed staining in most samples, although different in distribution and intensity. Staining of endometrial glands was seen in unevenly distributed cells or cell clusters. In contrast, for endocervical glands, labelling was observed distinctly on basally located cells (reserve cells) and at the subapical side of luminal cells. Faint labelling of the basal cell layer was also observed in squamous epithelia. It was more pronounced in severe cervical dysplasia and carcinoma in situ. In carcinomas of glandular origin, dedifferentiation was accompanied by an increase in cytoplasmic labelling, whereas the intensity of staining was not related to differentiation in squamous cell carcinomas. While data derived from Northern blots are suggestive of c-erbB-2 overexpression to indicate an advanced and dedifferentiated state of tumours of glandular origin, staining with an anti-ERBB-2 antibody occurred in both normal and atypical squamous and glandular epithelia and may indicate regular proliferation and/or differentiation-associated events.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980167     DOI: 10.1007/bf01625727

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  23 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

3.  The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues.

Authors:  C R De Potter; S Van Daele; M J Van de Vijver; C Pauwels; G Maertens; J De Boever; D Vandekerckhove; H Roels
Journal:  Histopathology       Date:  1989-10       Impact factor: 5.087

4.  Keratin and tissue polypeptide antigen profiles of the cervical mucosa.

Authors:  T Löning; C Kühler; J Caselitz; H E Stegner
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours.

Authors:  C Brumm; C Schulze; K Charels; T Morohoshi; G Klöppel
Journal:  Histopathology       Date:  1989-05       Impact factor: 5.087

7.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor.

Authors:  T Yamamoto; S Ikawa; T Akiyama; K Semba; N Nomura; N Miyajima; T Saito; K Toyoshima
Journal:  Nature       Date:  1986 Jan 16-22       Impact factor: 49.962

8.  Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer.

Authors:  N R Lemoine; S Staddon; C Dickson; D M Barnes; W J Gullick
Journal:  Oncogene       Date:  1990-02       Impact factor: 9.867

9.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor.

Authors:  A L Schechter; M C Hung; L Vaidyanathan; R A Weinberg; T L Yang-Feng; U Francke; A Ullrich; L Coussens
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

10.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

View more
  3 in total

1.  Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.

Authors:  C Uzan; E Darai; A Valent; O Graesslin; A Cortez; R Rouzier; P Vielh
Journal:  Virchows Arch       Date:  2009-03-18       Impact factor: 4.064

2.  Prognostic value of c-erbB-2 expression in uterine cervical carcinoma.

Authors:  R J Hale; C H Buckley; H Fox; J Williams
Journal:  J Clin Pathol       Date:  1992-07       Impact factor: 3.411

3.  p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions.

Authors:  D Kamel; Y Soini; K Nuorva; A Khalifa; A Mangoud; K Vähäkangas; P Pääkkö
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.